切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2021, Vol. 15 ›› Issue (02) : 82 -89. doi: 10.3877/cma.j.issn.1674-0807.2021.02.004

所属专题: 文献

论著

平消胶囊对实验性乳腺癌的作用
钟海林1, 蔡林2, 孙阳3,(), 陈贵娥4, 唐源4, 李宇华4, 董明芝5, 刘铁明5, 梅其炳3   
  1. 1. 524005 湛江,南部战区海军第一医院耳鼻喉科
    2. 541002 桂林,解放军联勤保障部队第924医院药剂科
    3. 710032 西安,空军军医大学药理教研室 国家中药胃肠药理重点实验室
    4. 524005 湛江,南部战区海军第一医院药剂科
    5. 710043 西安正大制药有限公司
  • 收稿日期:2018-12-10 出版日期:2021-04-01
  • 通信作者: 孙阳

Effect of Pingxiao capsuless on experimental breast cancer

Hailin Zhong1, Lin Cai2, Yang Sun3,(), Guie Chen4, Yuan Tang4, Yuhua Li4, Mingzhi Dong5, Tieming Liu5, Qibing Mei3   

  1. 1. Department of Otolaryngology, First Naval Force Hospital of Southern Theater Command, Zhanjiang 524005, China
    2. Department of Pharmacy, No. 924 Hospital of People’s Liberation Army Joint Logistic Support Force, Guilin 541002, China
    3. Department of Pharmacology, State Key Laboratory of Gastrointestinal Pharmacology of Traditional Chinese Medicine, Medical University of Air Forces, Xi’an 710032, China
    4. Department of Pharmacy, First Naval Force Hospital of Southern Theater Command, Zhanjiang 524005, China
    5. Xi’an C. P. Pharmaceutical Co., Ltd., Xi’an 710043, China
  • Received:2018-12-10 Published:2021-04-01
  • Corresponding author: Yang Sun
引用本文:

钟海林, 蔡林, 孙阳, 陈贵娥, 唐源, 李宇华, 董明芝, 刘铁明, 梅其炳. 平消胶囊对实验性乳腺癌的作用[J/OL]. 中华乳腺病杂志(电子版), 2021, 15(02): 82-89.

Hailin Zhong, Lin Cai, Yang Sun, Guie Chen, Yuan Tang, Yuhua Li, Mingzhi Dong, Tieming Liu, Qibing Mei. Effect of Pingxiao capsuless on experimental breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2021, 15(02): 82-89.

目的

观察平消胶囊对实验性乳腺癌的作用。

方法

将36只SD雌性大鼠随机分为6组:正常组、模型组、他莫昔芬组(0.36 mg/kg)以及平消胶囊低(250 mg/kg)、中(500 mg/kg)、高(750 mg/kg)剂量组。采用腹腔注射二甲基苯蒽(DMBA,80 mg/kg)的方法建立大鼠乳腺癌模型,建模3 d后给予药物干预,正常组大鼠给予正常饮食,25周后观察乳腺肿瘤发生情况及进行组织病理学分析;并用酶联免疫吸附试验(ELISA)检测大鼠血清中雌二醇(E2)、谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)、肿瘤坏死因子α(TNF-α)水平变化;观察大鼠脏器指数的变化。多组间比较采用单因素方差分析,重复测量数据采用重复测量的方差分析,两两比较采用LSD法。

结果

(1)大鼠体质量经重复测量方差分析显示,时间因素、分组因素以及时间与分组的交互作用均对大鼠体质量有影响(F=70.385,P<0.001;F=19.389,P<0.001;F=3.184,P=0.020)。(2)模型组大鼠双侧乳腺均发生肿瘤,给予他莫昔芬及平消胶囊干预后,大鼠只发生单侧乳腺肿瘤;模型组乳腺肿瘤体积为(21.5±9.6) cm3,他莫昔芬组及平消胶囊低、中、高剂量组乳腺肿瘤体积分别为(13.6±9.6)、(20.1±5.3)、(15.5±6.2)、(5.2±2.3) cm3,其中高剂量组乳腺肿瘤体积与模型组比较,差异有统计学意义(P<0.050)。(3)各组大鼠双侧第二乳头直径的差异有统计学意义(右侧:F=11.378, P<0.001;左侧:F=9.600,P<0.001),组间两两比较显示:模型组分别与他莫昔芬组以及平消胶囊中、高剂量组比较,差异均有统计学意义(P均<0.050);他莫昔芬组与平消胶囊低剂量组比较,差异也有统计学意义(P<0.050)。(4)各组大鼠血清中E2、GSH-Px、SOD、MDA、TNF-α水平差异均有统计学意义(F=64.845、60.303、32.583、80.558、46.740,P均<0.001)。其中,模型组与正常组比较,E2、MDA、TNF-α水平明显升高(P均<0.050),GSH-Px、SOD水平明显降低(P均<0.050);模型组分别与他莫昔芬组、平消胶囊中剂量及高剂量组比较,E2、GSH-Px、SOD、MDA、TNF-α水平的差异均有统计学意义(P均<0.050),他莫昔芬组分别与平消胶囊中、高剂量组比较,E2、GSH-Px、SOD、MDA水平的差异均有统计学意义(P均<0.050)。(5)各组间子宫、胸腺、脾脏、肝脏及肾脏脏器指数的差异均有统计学意义(F=3.502、1.696、13.672、2.995、4.465,P均<0.050),其中,模型组分别与正常组、他莫昔芬组以及平消胶囊中、高剂量组比较,子宫、胸腺、脾脏脏器指数的差异均有统计学意义(P均<0.050),他莫昔芬组分别与平消胶囊低、中、高剂量组比较,差异均无统计学意义(P均>0.050)。HE染色结果显示,平消胶囊中、高剂量组大鼠的乳腺瘤样变化程度减轻,腺泡数量减小,导管增生和扩张也有明显改善,病变明显减轻。

结论

平消胶囊对DMBA诱导的大鼠乳腺癌病变具有显著的防治作用,其作用机制可能与其调节血清中E2、GSH-Px、SOD、MDA、TNF-α水平,调节机体氧化应激状态,进而提高机体免疫调节水平有关。

Objective

To observe the effect of Pingxiao capsules on experimental breast cancer.

Methods

The 36 female SD rats were randomly divided into 6 groups: normal group, model group, tamoxifen group (0.36 mg/kg), low-dose Pingxiao capsule group (250 mg/kg), medium-dose group (500 mg/kg) and high-dose group (750 mg/kg). The rat model of breast cancer was established by intraperitoneal injection of 7, 12-dimethylbenz[a]anthracene (DMBA, 80 mg/kg). After 3 days, the rats had normal diet in normal group, while the rats were given drug intervention in other groups. After 25 weeks, the rats were observed for breast tumor and histopathological analysis was performed. Enzyme-linked immunosorbent assay (ELISA) was used to detect the levels of estradiol (E2), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), malondialdehyde (MDA) and tumor necrosis factor α (TNF-α) in serum of rats. The changes of viscera mass index in rats were observed. The analysis of variance (ANOVA) was used for comparison among multiple groups, and the LSD method was used for pairwise comparison. Repeated measurement data were analyzed by repeated measures of ANOVA.

Results

(1) The repeated measures of ANOVA showed that time, grouping and interaction between time and grouping all affected body weight of rats (F=70.385, P < 0.001; F=19.389, P < 0.001; F = 3.184, P = 0.020). (2) The rats in model group had bilateral breast tumors, while the rats only had unilateral breast tumor after intervention of tamoxifen and Pingxiao capsules. The tumor volume in model group was (21.5±9.6) cm3. The breast tumor volume was (13.6±9.6), (20.1±5.3), (15.5±6.2), (5.2±2.3) cm3 in tamoxifen group, low-dose Pingxiao capsule group, medium-dose group and high-dose group, respectively. The breast tumor volume presented a significant difference between high-dose group and model group (P < 0.050). (3) The diameter of bilateral second nipples presented a significant difference among groups (right: F=11.378, P<0.001; left: F=9.600, P<0.001). Pairwise comparison showed that there were significant differences between model group and tamoxifen group/medium-dose Pingxiao capsule group/high-dose group (all P<0.050). There was a significant difference in nipple diameter between tamoxifen group and low-dose Pingxiao capsule group (P<0.050). (4) There were significant differences in serum levels of E2, GSH-Px, SOD, MDA and TNF-α among groups (F=64.845, 60.303, 32.583, 80.558, 46.740, all P< 0.050). Compared with the normal group, the levels of E2, MDA and TNF-α in model group were significantly increased (all P< 0.050), while the levels of GSH-Px and SOD were significantly decreased (all P< 0.050). There were significant differences in the levels of E2, GSH-Px, SOD, MDA and TNF-α between model group and tamoxifen group/medium-dose Pingxiao capsule group/high-dose group (all P < 0.050); the levels of E2, GSH-Px, SOD and MDA all presented significant differences between tamoxifen group and medium-dose/high-dose Pingxiao capsule group (all P< 0.050). (5) The viscera mass index of the uterus, thymus, spleen, liver and kidneys presented a significant difference among groups (F=3.502, 1.696, 13.672, 2.995, 4.465, all P<0.050). Compared with model group, the viscera mass index of the uterus, thymus and spleen in normal group, tamoxifen group, medium-dose Pingxiao capsule group and high-dose group all presented a significant difference (all P< 0.050); there was a significant difference between tamoxifen group and low-dose/medium-dose/high-dose Pingxiao capsule group (all P>0.050). The results of HE staining showed that in medium-dose Pingxiao capsule group and high-dose group, the rats had significantly improved mammary tumor-like changes, hyperplasia and expansion of ducts, less acini and relieved lesions.

Conclusion

Pingxiao capsules are effective in prevention and treatment of DMBA-induced breast cancer in rats, which be due to its regulation on serum E2, GSH-Px, SOD, MDA and TNF-α levels, as well as oxidative stress state of the body, thus improving the immune regulation.

表1 平消胶囊对实验性乳腺癌模型大鼠体质量的影响(g,±s)
图1 实验性乳腺癌模型大鼠肿瘤发生情况 a~f图分别为正常组、模型组、他莫昔芬组以及平消胶囊低(250 mg/kg)、中(500 mg/kg)、高(750 mg/kg)剂量组大鼠
表2 平消胶囊对实验性乳腺癌模型大鼠肿瘤体积的影响
表3 平消胶囊对实验性乳腺癌模型大鼠第二乳头直径的影响(mm,±s)
图2 平消胶囊对实验性乳腺癌模型大鼠乳腺组织病理形态的影响(HE ×100) a~f图分别所示正常组、模型对照组、他莫昔芬组以及平消胶囊低(250 mg/kg)、中(500 mg/kg)、高(750 mg/kg)剂量组的乳腺组织病理图
表4 平消胶囊对实验性乳腺癌模型大鼠E2、GSH-Px、SOD、MDA、TNF-α分泌水平的影响(±s)
表5 平消胶囊对实验性乳腺癌模型大鼠脏器指数的影响(%,±s)
[1]
DeSantis CE, Fedewa SA, Goding Sauer A,et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women [J]. CA Cancer J Clin,2016,66(1):31-42.
[2]
Fan L, Strasser-Weippl K, Li JJ,et al. Breast cancer in China[J]. Lancet Oncol,2014,15(7):279-289.
[3]
Siege R, Ma J, Zou Z,et al. Cancer statistics,2014[J]. CA Cancer J Clin,2014,64 (5):364.
[4]
王慧杰,王朝霞,万冬桂,等. 乳腺癌分子分型指导下的中医治疗思路与方法[J]. 中国中西医结合杂志,2016, 36 (4):480-483.
[5]
张洁慧. 乳腺癌术后预后影响因素分析[J]. 健康研究,2016,36(3):340-341.
[6]
Das Gupta S, So JY, Wall B,et al. Tocopherols inhibit oxidative and nitrosative stress in estrogen-induced early mammary hyperplasia in ACI rats[J]. Mol Carcinog,2015,54(9):916-925.
[7]
黄凌曦. 激素替代治疗与乳腺癌发病风险的关系[J/CD].中华乳腺病杂志(电子版), 2011,5(1):77-81.
[8]
王娟,岳正刚,董明芝,等. 平消胶囊的抗肿瘤作用及其机制研究[J]. 中华中医药杂志,2017.32(10):4658-4663.
[9]
邹利光,张松,戚跃勇,等. 二甲基苯蒽诱发大鼠乳腺癌的病理及淋巴管生成的研究[J],实用癌症杂志,2012,27(1):1-3.
[10]
何云山,惠华英,喻嵘,等.芦笋对高脂饮食小鼠脏器指数及血生化的影响[J].中国微生态学杂志,2018,30(11):1261-1265.
[11]
郑荣寿,孙可欣,张思维,等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[12]
伍睿昕,董昌盛. 中医分期辨证治疗乳腺癌研究进展[J]. 中国中医药现代远程教育,2018,16(18):139-142.
[13]
马云飞,孙旭,念家云,等. 乳腺癌中医证候研究进展与思考[J]. 中华中医药杂志,2018,33(8):3495-3497.
[14]
温惠红,欧阳学认,陈永旭,等. 中医药对乳腺癌内分泌治疗相关性血脂异常的研究进展[J]. 现代医院,2018,18(6):875-878,882.
[15]
谢迪迪,姜大庆. 中医药干预乳腺癌内分泌治疗不良反应的研究进展[J]. 齐齐哈尔医学院学报,2017,38(8):949-950.
[16]
孙晓寅,莊志刚. 性激素与乳腺癌关系的研究进展[J]. 中国新药与临床杂志,2018,37(9):35-40.
[17]
康欣梅,王丽,付小娜,等. 血清性激素与乳腺密度和绝经后女性乳腺癌的相关性研究[J]. 哈尔滨医科大学学报,2014,48(5):386-389.
[18]
黎思毅,彭红娟. 乳腺癌组织氧化应激反应指标的变化[J]. 实用医学杂志,2009,25(16):2626-2627.
[19]
朱坤,丁米娜,李月,等. 蒲公英萜醇对乳腺癌细胞增殖及发生氧化应激反应的影响[J]. 当代医药论丛,2017,15(19):10-12.
[20]
López-Lázaro M. Dual role of hydrogen peroxide in cancer:possible relevance to cancer chemoprevention and therapy[J]. Cancer Lett,2007,252(1):1-8.
[21]
郑华. 5-氟尿嘧啶、阿霉素、环磷酰胺联合化疗对乳腺癌患者血清抗氧化酶、肝脏转氨酶和心肌酶的影响分析[J]. 中国医药指南,2017,15(33):183-184.
[22]
乐音子,卞卫和,姚昶,等. 自拟红黄抗氧化方抑制乳腺癌患者化疗期氧化应激反应临床研究[J]. 中国中医药信息杂志,2014,21(7):11-14.
[23]
Deepalakshmi K, Mirunalini S, Krishnaveni M, et al. In vitro and in vivo antioxidant potentials of an ethanolic extract of Ganoderma lucidum in rat mammary carcinogenesis[J].Chin J Nat Med, 2013, 11(6): 621-627.
[24]
黄景慧,尤冬山,陈欣,等. 晚期乳腺癌患者行FAC方案化疗对体内氧化应激水平的影响[J]. 疑难病杂志,2017,16(4):377-380,384.
[25]
林曼. 乳腺癌患者血清TNF-α和IL-6水平观察及临床意义[J]. 中国实用医药,2017,12(19):51-52.
[26]
曹加伟,黄梅,严晶,等. 针刺对DMBA诱导的乳腺癌大鼠ER、PR表达的影响[J]. 上海针灸杂志,2016,35(3):344-348.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要